Enanta Pharmaceuticals (ENTA) Net Income towards Common Stockholders Growth (5y) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Enanta Pharmaceuticals | 367.22 Mn | 203.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18.44% |
| Dec 31, 2025 | -7.47% |
| Sep 30, 2025 | 8.62% |
| Jun 30, 2025 | -5.06% |
| Mar 31, 2025 | -30.40% |
| Dec 31, 2024 | -29.61% |
| Sep 30, 2024 | -38.60% |
| Jun 30, 2024 | -39.17% |
| Mar 31, 2024 | -56.93% |
| Dec 31, 2023 | -26.85% |
| Sep 30, 2023 | -24.78% |
| Jun 30, 2023 | -31.46% |
| Mar 31, 2023 | -37.97% |
| Dec 31, 2022 | -34.97% |
| Sep 30, 2022 | -18.73% |
| Jun 30, 2022 | -13.77% |
| Mar 31, 2022 | -21.82% |
| Dec 31, 2021 | -30.15% |
| Sep 30, 2021 | -88.36% |
| Jun 30, 2021 | -158.53% |
| Mar 31, 2021 | -93.11% |
| Dec 31, 2020 | -16.89% |
| Sep 30, 2020 | -68.26% |
| Jun 30, 2020 | -61.93% |
| Mar 31, 2020 | -15.86% |
| Dec 31, 2019 | -32.92% |
| Sep 30, 2019 | 30.76% |
| Jun 30, 2019 | -32.46% |
| Mar 31, 2019 | 22.84% |
| Dec 31, 2018 | 46.91% |
| Sep 30, 2018 | 52.22% |
| Jun 30, 2018 | 47.17% |
| Mar 31, 2018 | 35.18% |
| Dec 31, 2017 | 44.31% |
| Sep 30, 2017 | 178.80% |
| Jun 30, 2017 | -28.05% |
| Mar 31, 2017 | -46.57% |